Meeting the GLP-1 Challenge with High-Resolution Mass Spec
Veloxity Labs and SCIEX team up to advance peptide bioanalysis; here, the teams discuss how the GLP-1 boom is reshaping workflows and raising the bar for analytical performance
By
James Strachan
February 25, 2026
Clinical Scorecard: Meeting the GLP-1 Challenge with High-Resolution Mass Spec
At a Glance
Category Detail
Condition Peptide Therapeutics Analysis Key Mechanisms High-resolution accurate-mass (HRAM) mass spectrometry enhances sensitivity, selectivity, and speed in peptide bioanalysis. Target Population Patients undergoing peptide therapeutic treatments, particularly those requiring GLP-1 receptor agonists. Care Setting Bioanalytical laboratories and clinical trial environments.
Key Highlights
HRAM systems like SCIEX ZenoTOF 8600 improve selectivity and sensitivity for peptide analysis. Smaller sample volumes and lower limits of quantification (LLOQs) are critical for modern clinical trials. The combination of HRAM and triple-quads provides flexibility and efficiency in peptide workflows. Guideline-Based Recommendations
Diagnosis
Utilize HRAM for selective quantitative analysis in complex matrices. Management
Implement phase-appropriate method design and small-volume workflows. Monitoring & Follow-up
Adhere to ICH M10 guidelines for method development and validation. Risks
Matrix interferences and the need for intact confirmation can complicate analysis. Patient & Prescribing Data
Individuals receiving GLP-1 receptor agonist therapies.
Emerging peptide therapeutics require advanced analytical methods to ensure accurate dosing and efficacy.
Clinical Best Practices
Adopt automated workflows to enhance throughput and reproducibility. Employ optimized sample preparation techniques to maximize recovery of peptides. References
